Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 24, 2025

ING Group completes two risk sharing transactions

View original at globenewswire.com
ING Group completes two risk sharing transactions ING Group completes two risk sharing transactions ING Group today announced the successful completion of two significant risk transfer (SRT) transactions, marking the inaugural SRTs for ING Wholesale Banking…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With the SRT transactions, ING strengthens its ability to serve corporate clients by freeing up resources to finance new growth opportunities

    80% confidence
  • The SRT transactions provide first-loss protection on diversified portfolios of corporate loans with a total notional exposure of €10.5 billion

    80% confidence
  • ING aims to extend the strategic use of SRTs across Retail and additional Wholesale Banking portfolios in the coming years

    80% confidence
  • ING Bank has more than 60,000 employees offering retail and wholesale banking services to customers in over 100 countries

    80% confidence
  • The transactions are expected to reduce ING's risk-weighted assets by €3.4 billion, resulting in a pro forma impact of +14 basis points on the 3Q2025 CET1 ratio

    80% confidence
  • ING's management of ESG material risk is 'Strong' with an ESG risk rating of 18.0 (low risk) as of June 2025

    80% confidence
  • The SRT transactions are a milestone in ING's capital velocity strategy, enabled by outstanding teamwork and strong partnerships with leading institutional investors

    80% confidence
  • ING's ESG rating has been upgraded from 'AA' to 'AAA' in October 2025

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
ING Group completes two risk sharing transactions — Source | Via News | Via News